Sinopse

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Episódios

  • Key Considerations for Initiating a Chronic Lymphocytic Leukemia Therapy

    Key Considerations for Initiating a Chronic Lymphocytic Leukemia Therapy

    30/09/2020

    Guest: Lisa Nodzon PhD, ARNP, AOCNP No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.

  • Looking Out for Neutropenia in Chronic Lymphocytic Leukemia

    Looking Out for Neutropenia in Chronic Lymphocytic Leukemia

    30/09/2020

    Guest: Lisa Nodzon PhD, ARNP, AOCNP Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.

  • Prevalence of Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Prevalence of Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    16/09/2020

    Host: Richard K. Bogan, MD While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night. Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy. This promotional, non-CME program is intended for U.S. physicians treating OSA. Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc. © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved. US-SLE-20004

  • Pathophysiology of Obstructive Sleep Apnea  Its Role in Excessive Daytime Sleepiness

    Pathophysiology of Obstructive Sleep Apnea & Its Role in Excessive Daytime Sleepiness

    16/09/2020

    Guest: Richard K. Bogan, MD Emerging science can help us better understand the link between obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). While many factors, such as insufficient sleep, medication, or comorbid disorders, can cause your patients with OSA to feel sleepy, chronic sleep disruption and chronic intermittent hypoxia associated with OSA may also contribute to EDS. Here to discuss the important physiologic changes to gray and white matter that may occur in OSA and lead to EDS is Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc. This promotional, non-CME program is intended for U.S. physicians treating OSA. Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc. © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved. US-SLE-2000467 Rev0920

  • Challenges in Identifying, Assessing,  Monitoring Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    Challenges in Identifying, Assessing, & Monitoring Excessive Daytime Sleepiness in Obstructive Sleep Apnea

    16/09/2020

    Guest: Paul Doghramji, MD Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences. Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice. This promotional, non-CME program is intended for U.S. physicians treating OSA. © 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved. US-SLE-2000467 Rev0920

  • Adverse Event Detection  Reporting: What Healthcare Providers Need to Know

    Adverse Event Detection & Reporting: What Healthcare Providers Need to Know

    15/09/2020

    Host: Matt Birnholz, MD Guest: Jessica Ailani, MD What should you do if a patient uses a prescribed medication and experiences an adverse event? Here to walk us through what clinicians need to keep in mind when detecting and reporting adverse events is Dr. Jessica Ailani, Vice Chair of Strategic Planning in Medstar Georgetown Department of Neurology at Medstar Georgetown University Hospital in Washington, DC. USA-334-83979

  • Achieving Clearer Skin with a Rosacea Treatment

    Achieving Clearer Skin with a Rosacea Treatment

    10/09/2020

    Host: Jennifer Caudle, DO Guest: Hilary Baldwin, MD How can we help the more than 16 million Americans living with rosacea achieve clearer skin using the current therapeutic landscape?

  • Rosacea’s Impact Is more than Skin Deep…Shifting Treatment Paradigms

    Rosacea’s Impact Is more than Skin Deep…Shifting Treatment Paradigms

    02/09/2020

    Guest: Hilary Baldwin, MD When issues seen on the skin’s surface are combined with the non-visible symptoms of rosacea, like stinging, burning, and itching, the physical and psychological tolls on quality of life become profound. That’s why it’s so important for clinicians to take advantage of the available treatment options like SOOLANTRA (ivermectin) Cream, 1% to help patients with the inflammatory lesions of rosacea, as Dr. Hilary Baldwin explains.

  • When Were Oral PPAs Considered for PAH Patients in Common Clinical Scenarios?

    When Were Oral PPAs Considered for PAH Patients in Common Clinical Scenarios?

    02/09/2020

    Host: Jennifer Caudle, DO Guest: Victor F Tapson, MD Please see the full Prescribing Information here. This program is intended for US healthcare professionals only and is not certified for continuing medical education. Sponsored by Actelion Pharmaceuticals US, Inc., the marketer and distributor of UPTRAVI® (selexipag). Although there is currently no cure, the treatment of pulmonary arterial hypertension (PAH) has evolved substantially and its impact on patients varies based on clinical factors, including etiology, functional class, and hemodynamic parameters.Dr. Jennifer Caudle is joined by pulmonologist Dr. Victor Tapson, Professor of Medicine at Cedars-Sinai Medical Center, to discuss results from the Prostacyclin International Expert Panel consensus survey on common clinical scenarios in which they considered adding oral prostacyclin pathway agents in patients with PAH. ABOUT THE PROSTACYCLIN INTERNATIONAL EXPERT PANEL CONSENSUS OPINIONSThe Prostacyclin International Expert Panel was not a consensu

  • Unleash the Truth About COPD

    Unleash the Truth About COPD

    17/08/2020

    Guest: MeiLan K. Han, MD, MS For patients with COPD, exacerbations can have an irreversible and sustained impact on their daily life.3,4 Additionally, exacerbations are often underreported.5 That’s why Dr. MeiLan Han is here to walk us through the importance of exacerbation recognition and prevention, the health and life burdens of exacerbations, and patient-physician communication gaps. References: Halpin DMG, Decramer M, Celli BR, et al. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85-91. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097. O’Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109-115. Roche N. Activity limitation: a major consequence of dyspnoea in COPD. Eur Respir Rev. 2009;18(112):54-5

  • Clinical Trial Data Evaluating a Treatment for Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) in Patients With Active Cancer

    Clinical Trial Data Evaluating a Treatment for Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) in Patients With Active Cancer

    17/08/2020

    Host: Jennifer Caudle, DO Guest: Steven Fein, MD Here to delve into venous thromboembolism (VTE) clinical trial data on XARELTO®, a treatment option approved for deep vein thrombosis (DVT) and pulmonary embolism (PE), is Dr Steven Fein. He will highlight the EINSTEIN clinical trials, a subgroup analysis, and the results of a randomized, open-label pilot trial for the treatment of DVT and/or PE in patients with active cancer. This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultant is a paid speaker for Janssen Pharmaceuticals, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen. ©Janssen Pharmaceuticals, Inc. 2020 August 2020 cp-145201v1

  • Women and Heart Health: Improving Care with Knowledge and Cardiovascular Risk Assessment Tools

    Women and Heart Health: Improving Care with Knowledge and Cardiovascular Risk Assessment Tools

    13/08/2020

    Host: Jay Wohlgemuth, MD Guest: Felice Gersh, MD The number one cause of death for women in the United States is cardiovascular disease. Luckily, providers can help identify their patients’ risk and educate them on the preventive measures available that can help mitigate their risk. Listen in as Dr. Jay Wohlgemuth speaks with Dr. Felice Gersh about diagnostic tests available for women today.

  • The Evolution of Testosterone Replacement Therapy

    The Evolution of Testosterone Replacement Therapy

    04/08/2020

    Host: Jennifer Caudle, DO Guest: Paresh Dandona, MD, PhD Guest: Stanton Honig, MD Join Dr. Jennifer Caudle as she welcomes Dr. Paresh Dandona and Dr. Stanton Honig to discuss testosterone replacement therapy and an oral softgel option for appropriate hypogonadal men. This program reviews the history of clinical hypogonadism and testosterone replacement therapies in addition to JATENZO®, the first and only FDA-approved oral softgel testosterone undecanoate. Please see Important Safety Information and Prescribing Information, including BOXED WARNING on increases in blood pressure.

  • An Advancement in Oral Testosterone Replacement Therapy

    An Advancement in Oral Testosterone Replacement Therapy

    04/08/2020

    Host: Jennifer Caudle, DO Guest: Faysal A. Yafi, MD, FRCSC Guest: Adrian S. Dobs, MD, MHS Join Dr. Jennifer Caudle as she welcomes Dr. Adrian Dobs and Dr. Faysal Yafi to discuss testosterone replacement therapy and an oral softgel option for appropriate hypogonadal men. Topics in this program include safety results from inTUne, the Phase 3, randomized, open-label study of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy. Please see Important Safety Information and Prescribing Information, including BOXED WARNING on increases in blood pressure.

  • Reducing Healthcare Utilization with Peptide-Based Diets in Intolerant Home Enteral Nutrition Patients

    Reducing Healthcare Utilization with Peptide-Based Diets in Intolerant Home Enteral Nutrition Patients

    30/07/2020

    Guest: Manpreet Mundi, MD Despite the increasing prevalence of home enteral nutrition over the last few decades, there has not been an equal rise in the number of studies being conducted in this population, which makes it difficult to develop guidelines and answer key clinical questions. So to help address this gap, the home enteral nutrition team at Mayo Clinic conducted a retrospective analysis of patients who utilized peptide-based diets, and now, Dr. Manpreet Mundi is here to share the results of that analysis.

  • QNatal® Advanced: Understanding Prenatal Screening

    QNatal® Advanced: Understanding Prenatal Screening

    23/07/2020

    Guest: Carrie Guy QNatal® Advanced is a noninvasive, prenatal, cell-free DNA (cfDNA) screen that can be ordered as early as 10 weeks gestation. This test utilizes Next-Generation Sequencing (NGS) technology and superior bioinformatics to ensure high sensitivity, specificity, and PPV. Here to walk us through the QNatal Advanced screening test and how the results are reported is Carrie Guy, a Certified Genetic Counselor and the Product Manager for Women's Health at Quest Diagnostics.

  • NIPT: Tips for Counseling Your Patient

    NIPT: Tips for Counseling Your Patient

    22/07/2020

    Host: Kelly Chen, MS, LCGC Joining us is Senior Genetic Counselor Kelly Chen, who shares some counseling tips clinicians can use when talking to patients about non-invasive prenatal testing (NIPT), key factors to consider when reviewing an NIPT result, and the three potential results of the Harmony prenatal test, which screens for Down syndrome, trisomy 18, and trisomy 13. Kelly Chen, MS, LCGC, is no longer employed nor associated with Roche Diagnostics

  • Family Planning in Multiple Sclerosis: Enhancing Patient Care

    Family Planning in Multiple Sclerosis: Enhancing Patient Care

    16/07/2020

    Host: Matt Birnholz, MD Guest: Maria K. Houtchens, MD Guest: Maria Lopes, MD Patients with multiple sclerosis (MS) are increasingly choosing to start families. It is incumbent on us as healthcare professionals to try to ensure their chances for healthy pregnancies while maintaining adequate disease control. In this program, Dr. Houtchens and Dr. Lopes discuss the importance of patient/healthcare provider partnerships in family planning. Specific points of focus include the role of effective contraception, key concepts regarding the use of disease modifying therapies, and important practical considerations related to patient care in the time before, during, and after pregnancy. EMD Serono is a business of Merck KGaA, Darmstadt, Germany. ©EMD Serono, Inc. All rights reserved. US/NPR/1019/0558a

  • Innovative Nutritional Intervention: A Science-Based Approach to Supporting Metabolic Health

    Innovative Nutritional Intervention: A Science-Based Approach to Supporting Metabolic Health

    01/07/2020

    Host: Jennifer Caudle, DO Guest: Joanna Mitri, MD, MS Guest: Pouya Shafipour, MD There are numerous studies being conducted around the world examining various fasting modalities and their impact on the body and overall health. One increasingly popular approach is the Fasting Mimicking Diet® (FMD®). In this informative video you’ll gain a greater understanding of how this new and exciting nutritional intervention compares with other types of fasts, and how it works to elicit a host of positive effects that can help support healthy aging. Tune in as Drs. Joanna Mitri and Pouya Shafipour share their expertise on the topic of fasting, and the extraordinary benefits that can be achieved through the FMD. And for the ultimate nutritional intervention for supporting and maintaining metabolic health, there’s ProLon Professional— a thoroughly researched, 5-day, plant-based meal program designed to get your patients get back on track and be as effective as 120 days of Mediterranean Diet in just 4 cycles of the

  • CINtec PLUS Cytology: A New Biomarker-Based Triage in Cervical Cancer Screening

    CINtec PLUS Cytology: A New Biomarker-Based Triage in Cervical Cancer Screening

    30/06/2020

    Host: Jennifer Caudle, DO Guest: Ritu Nayar, MD The Pap test has played a key role in reducing cervical cancer since its introduction in the 1940s, but like any test, it isn’t without its limitations. Joining Dr. Jennifer Caudle to discuss how CINtec PLUS Cytology, a biomarker-based cytology test, aims to overcome those challenges is Dr. Ritu Nayar.

página 1 de 3

Informações: